19 August 2026

Corrective Disclosure

Doctor Care Anywhere Group PLC (ASX:DOC, “Doctor Care Anywhere” or “the Company”) today advises of corrective disclosure pursuant to ASX : Listing Rules 3.10.3A, 3.10.3B, 3.10.3E, and 3.19A.2.

Share Option Review and Correction of Director Interest Notices

Doctor Care Anywhere Group PLC (ASX: DOC) (the Company) today lodges Appendix 2A, 3G, 3H & 3Y notices in respect of two directors, and advises that those notices were not lodged within the periods required under the relevant ASX Listing Rule notification requirements.

Director interest notices

The notices relate to the following changes in directors' interests:

- the grant of 2,500,000 options to Matthew Addison on 30 April 2026 (exercise price A$0.125, expiry 31 December 2026);
- the grant of 1,408,362 nil cost options to Laura O’Riordan on 30 April 2026 (expiry 30 April 2036);
- the cessation of 2,500,000 options held by Matthew Addison following their expiry on 31 December 2025, previously notified by the Company via Appendix 3H; and
- the exercise of 1,000,000 vested options by Matthew Addison, resulting in the issue of 423,077 CDIs on a net settlement basis. The cessation of the underlying options was previously reflected in the Company's Appendix 3H disclosure; however, no corresponding Appendix 3Y was lodged within the timeframe required under Listing Rule 3.19A. The issue of these CDIs increased the Company's quoted CDI balance from 366,642,246 to 367,065,323.

Each of these transactions was disclosed by the Company at the time, but the separate Appendix 2A, 3G & 3Y notifications had not been lodged within the required notification periods under the relevant ASX Listing Rules.

The grants made on 30 April 2026 were approved by security holders at the Company’s Annual General Meeting on 28 April 2026. The terms of each grant, together with the lapse of the earlier options and the Board’s decision not to seek a waiver of the Listing Rules to extend their exercise period, were set out in the Notice of Annual General Meeting released on 30 March 2026.

The instructions issued by the Company in April 2026 in connection with these grants did not flag the recipients as directors for the purposes of the separate Appendix 2A, 3G & 3Y obligation, and the notices were accordingly not prepared.

The omission was identified during the preparation of the Company’s quarterly securities reporting and has been rectified today.

Historical share option review

Separately, the Company has completed a comprehensive review of all employee, director and adviser option arrangements across the Group. The review was undertaken as a governance and compliance exercise following a change of company secretary, and covered all material historic option schemes.

The review concluded that a number of historic options had previously lapsed, expired, been forfeited or otherwise ceased in accordance with scheme rules, but had not been fully reflected in the Company’s reported option population.

The principal causes were employee departures and the operation of leaver provisions, expiry of contractual exercise periods, failure of performance conditions, forfeiture of unvested awards, and grants which were never completed through execution of the required acceptance documentation.

The Company has identified approximately 9.8million options which appear to have ceased but which remained included in its reported option population. An appendix 3H has been lodged today to reflect the cessation. The company has issued a further 3.9 million options, as stated above, which it has notified today via an appendix 3G. On that basis the reconciled live option population is approximately 68.8 million options, compared with a reported population of approximately 74.6 million options as at 8 July 2026. Following todays lodgements, the reported total will equal approximately 68.8 million.

Accounting review

The associated accounting review has been completed and the outcome will be reflected in the Company's H1 2026 reporting.

Remedial actions

The Company has implemented or is implementing the following:

- appointment of a Group General Counsel to strengthen governance, improve and securities administration and improve communication with the Australian governance support;
- mandatory identification of director and Key Management Personnel status for all securities transactions before ASX filings are prepared;
- separate tracking of Appendix 3Y obligations from the Company's Appendix 3G and 3H reporting;
- reconciliation of the Company's option population against registry and finance records at each securities lodgement;
- additional controls over option grant documentation, exercises, lapses and board approvals; and
- removal of reliance on legacy option schedules in favour of a single consolidated option register.

The Company takes its disclosure obligations seriously and regrets the omissions identified. The review has materially strengthened the integrity of the Company's share option records and the controls around them.

Amounts in this announcement are stated in sterling. Option exercise prices are stated in Australian dollars.

This announcement has been authorised for ASX release by The Board of Directors.

- ENDS –

About Doctor Care Anywhere

Doctor Care Anywhere Group PLC is one of the UK's leading private telehealth providers. The Company partners with insurers, healthcare providers, and corporate clients to deliver care through its proprietary digital health platform. Its growth strategy focuses on scaling services, expanding strategic partnerships, and leveraging data-driven healthcare solutions to improve patient outcomes and deliver long-term value for shareholders.

Engage with the Doctor Care Anywhere management team directly by asking questions, watching video summaries and seeing what other shareholders have to say. Navigate to our Interactive Investor hub here: https://investors.doctorcareanywhere.com/announcements

Subscribe to our news alert service: https://investors.doctorcareanywhere.com/s/db4283

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Doctor Care Anywhere Group plc	
ABN 645 163 873	

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Laura O'Riordan
Date of last notice	5 June 2025

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	- CDIs held Indirectly - Options held Directly
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Director's Spouse (Niall Kealy)
Date of change	30 April 2026
No. of securities held prior to change	- 500,000 CDIs - 30,000,000 Options
Class	Options
Number acquired	1,408,362 Options
Number disposed	0

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil cash consideration. The Options were granted on 30 April 2026 under the Company's Long Term Incentive Plan. The number of Options granted was determined by reference to an equity value of £104,923, converted to A$197,170.68 at an exchange rate of A$1.00:£0.53214 on the grant date, and divided by $!0.14 per CDI, being the volume weighted average price of the Company's CDIs traded on ASX over the twenty (20) trading days immediately preceding the grant date, resulting in the grant of 1,408,362 Options.
No. of securities held after change	- 500,000 CDIs - 31,408,362 Options
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Director Options under the Company's Long Term Incentive Plan with shareholder approval provided at the Company's Annual General Meeting held on 28 April 2026.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

+ See chapter 19 for defined terms.

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No.
If so, was prior written clearance provided to allow the trade to proceed during this period?	n/a
If prior written clearance was provided, on what date was this provided?	n/a

+ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Doctor Care Anywhere Group plc
ABN 645 163 873

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Matthew Addison
Date of last notice	6 November 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Directly
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	n/a

Date of change	31 December 2025 to 30 April 2026
No. of securities held prior to change	1. 3,500,000 options over DOC ordinary shares/CDIs as follows: • 1,000,000 options exercisable at **A$0.075 per share**[1] • 2,500,000 options exercisable at A$0.125 per share 2. 37,500 £1.00 convertible loan notes issued 10 January 2024 (convertible to 816,957 DOC ordinary shares/CDIs at a conversion price of £0.0459 per CDI. Conversion may be made no later than 10 days before 31 December 2027 unless DOC has redeemed the convertible loan notes before then, which it may do any time between 1 January 2026 and 31 December 2027)
Class	- Options - CDIs
Number acquired	- 2,500,000 Options (30 April 2026) - - 423,077 CDIs (30 April 2026)
Number disposed	- 1,000,000 Options (cancelled in return for the grant of 423,077 CDIs) - 2,500,000 Options (expired 31/12/2025)
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil cash consideration. 1,000,000 Options exercised on a net settlement basis at an exercise price of A$0.075 per option. The aggregate exercise price of A$75,000 was satisfied by the withholding of 576,923 CDIs, valued at the market price of A$0.13 per CDS, resulting in the delivery of 423,077 CDIs,
No. of securities held after change	1. 2,500,000 Options over DOC ordinary shares/CDIs
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	- Cancellation of 1,000,000 Options, with 423,077 CDIs issued by an exercise on a net settlement basis. - Expiry of 2,500,000 Options 31 December 2025. - Issue of 2,500,000 Director Options under the Company's Long Term Incentive Plan with shareholder approval 30 April 2026.

[1] Corrected from Appendix 3X filed 5/11/2024.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No.
If so, was prior written clearance provided to allow the trade to proceed during this period?	n/a
If prior written clearance was provided, on what date was this provided?	n/a

+ See chapter 19 for defined terms.